Adherence to bisphosphonate treatment by elderly women

被引:17
作者
Berecki-Gisolf, Janneke [1 ]
Hockey, Richard [1 ]
Dobson, Annette [1 ]
机构
[1] Univ Queensland, Fac Hlth Sci, Sch Populat Hlth, Herston, Qld 4006, Australia
来源
MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY | 2008年 / 15卷 / 05期
关键词
compliance; persistence; osteoporosis; alendronate;
D O I
10.1097/gme.0b013e31816be98a
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: The aim of this study was to evaluate the relationship between adherence to bisphosphonate treatment by postmenopausal women and demographic, health, and lifestyle factors before treatment in a country With universal Subsidies for pharmaceutical costs. Design: Older women participating in the Australian Longitudinal Study on Women's Health who consented to linking to Pharmaceutical Benefits Scheme claims data were included if they filled a bisphosphonate prescription between 2002 and 2005 after a medication-free interval of 180 days (N = 788). A Cox proportional hazards model was used to assess the association of baseline variables with duration of adherence to bisphosphonate treatment. Results: The median time until discontinuation of bisphosphonate treatment was 170 days (95% CI: 154-186). Accounting for socioeconomic status, the baseline variables that were associated with adherence failure were use of acid-related medications (hazard ratio 1.25, 95% CI 1.01-1.55) and smoking (hazard ratio 1.82, 95% CI 1.26-2.64); reporting high levels of physical activity was associated with better adherence (HR 0.69, 95% CI 0.52-0.92). Conclusions: Overall adherence to bisphosphonate treatment among older Australian women with a fracture history was poor. Inquiring about acid-related disorders and health behavior such as smoking and lack of physical activity could help the prescribing physician to identify women at risk of nonadherence.
引用
收藏
页码:984 / 990
页数:7
相关论文
共 30 条
[1]   The association between compliance and persistence with bisphosphonate therapy and fracture risk: A review [J].
Adachi, Jonathan ;
Lynch, Niall ;
Middelhoven, Hans ;
Hunjan, Manjit ;
Cowell, Warren .
BMC MUSCULOSKELETAL DISORDERS, 2007, 8 (1)
[2]  
Armstrong T., 2000, PHYS ACTIVITY PATTER
[3]   Upper gastrointestinal tract safety profile of alendronate -: The Fracture Intervention Trial [J].
Bauer, DC ;
Black, D ;
Ensrud, K ;
Thompson, D ;
Hochberg, M ;
Nevitt, M ;
Musliner, T ;
Freedholm, D .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (04) :517-525
[4]  
BAUMAN A, 1996, BEST PRACTICE PROMOT
[5]   Effects of continuing or stopping alendronate after 5 years of treatment - The Fracture Intervention Trial long-term extension (FLEX): A randomized trial [J].
Black, Dennis M. ;
Schwartz, Ann V. ;
Ensrud, Kristine E. ;
Cauley, Jane A. ;
Levis, Silvina ;
Quandt, Sara A. ;
Satterfield, Suzanne ;
Wallace, Robert B. ;
Bauer, Douglas C. ;
Palermo, Lisa ;
Wehren, Lois E. ;
Lombardi, Antonio ;
Santora, Arthur C. ;
Cummings, Steven R. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (24) :2927-2938
[6]   Ten years' experience with alendronate for osteoporosis in postmenopausal women [J].
Bone, HG ;
Hosking, D ;
Devogelaer, J ;
Tucci, JR ;
Emkey, RD ;
Tonino, RP ;
Rodriguez-Portales, JA ;
Downs, RW ;
Gupta, J ;
Santora, AC ;
Liberman, UA .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (12) :1189-1199
[7]   Gaps in treatment among users of osteoporosis medications: The dynamics of noncompliance [J].
Brookhart, M. Alan ;
Avorn, Jerry ;
Katz, Jeffrey N. ;
Finkelstein, Joel S. ;
Arnold, Marilyn ;
Polinski, Jennifer M. ;
Patrick, Amanda R. ;
Mogun, Helen ;
Solmon, Daniel H. .
AMERICAN JOURNAL OF MEDICINE, 2007, 120 (03) :251-256
[8]  
Brown WJ, 1998, WOMEN HEALTH, V28, P23
[9]   The impact of compliance with osteoporosis therapy on fracture rates in actual practice [J].
Caro, JJ ;
Ishak, KJ ;
Huybrechts, KF ;
Raggio, G ;
Naujoks, C .
OSTEOPOROSIS INTERNATIONAL, 2004, 15 (12) :1003-1008
[10]  
Catalan V S, 2000, Value Health, V3, P417, DOI 10.1046/j.1524-4733.2000.36006.x